Journal of hepato-biliary-pancreatic sciences · 2014
Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okada Ken-ichi, Kawai Manabu, Tani Masaji, Hirono Seiko, Miyazawa Motoki, Shimizu Atsushi, Kitahata Yuji, Yamaue Hiroki
Аннотация
BACKGROUND: The aim of the present study was to identify the predicting factors for unresectability and to clarify who should receive precise evaluations for distant metastasis and locally advanced unresectability in patients with pancreatic ductal adenocarcinoma (PDAC).
METHODS: A total of 200 consecutive patients with PDAC who presented to the outpatient clinic between June 2009 and October 2012 were analyzed retrospectively. Clinical factors and the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, DUPAN-2 (pancreatic cancer-associated antigen) and CA 125 were analyzed.
RESULTS: Of the 200 patients who were investigated for PDAC, 60 (30%) were initially considered unresectable (15 patients with locally advanced tumors, 45 patients with distant metastases). Of the 136 (68%) patients who were surgically explored, 19 (9.5%) were detected to have minute metastases on laparotomy. A multivariate analysis revealed that tumor size (≥30 mm) and abnormalities in the levels of DUPAN-2 and CA 125 were independent predictors of unresectability (P = 0.002, 0.014, < 0.001, respectively). The patients with triple positive findings presented with the highest sensitivity (78.8%) for unresectability.
CONCLUSIONS: Patients with triple positive findings for a tumor size ≥30 mm, abnormalities in the levels of DUPAN-2 and CA 125 should receive precise evaluations for unresectability.
METHODS: A total of 200 consecutive patients with PDAC who presented to the outpatient clinic between June 2009 and October 2012 were analyzed retrospectively. Clinical factors and the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, DUPAN-2 (pancreatic cancer-associated antigen) and CA 125 were analyzed.
RESULTS: Of the 200 patients who were investigated for PDAC, 60 (30%) were initially considered unresectable (15 patients with locally advanced tumors, 45 patients with distant metastases). Of the 136 (68%) patients who were surgically explored, 19 (9.5%) were detected to have minute metastases on laparotomy. A multivariate analysis revealed that tumor size (≥30 mm) and abnormalities in the levels of DUPAN-2 and CA 125 were independent predictors of unresectability (P = 0.002, 0.014, < 0.001, respectively). The patients with triple positive findings presented with the highest sensitivity (78.8%) for unresectability.
CONCLUSIONS: Patients with triple positive findings for a tumor size ≥30 mm, abnormalities in the levels of DUPAN-2 and CA 125 should receive precise evaluations for unresectability.
Предметные рубрики MeSH
AdenocarcinomaAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenCarcinoembryonic AntigenCarcinoma, Pancreatic DuctalFemaleHumansLaparoscopyMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsRetrospective StudiesRisk FactorsSensitivity and Specificity